Compare IMCR & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | ATAI |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2016 | 2025 |
| Metric | IMCR | ATAI |
|---|---|---|
| Price | $28.59 | $4.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $66.33 | $15.88 |
| AVG Volume (30 Days) | 432.7K | ★ 5.0M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $249,428,000.00 | $4,089,000.00 |
| Revenue This Year | $14.57 | N/A |
| Revenue Next Year | $8.21 | N/A |
| P/E Ratio | $114.16 | ★ N/A |
| Revenue Growth | 43.05 | ★ 1227.60 |
| 52 Week Low | $27.56 | $2.00 |
| 52 Week High | $40.71 | $6.73 |
| Indicator | IMCR | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.22 | 48.38 |
| Support Level | $27.66 | $4.00 |
| Resistance Level | $31.56 | $4.20 |
| Average True Range (ATR) | 1.21 | 0.33 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 51.86 | 29.69 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.